Related Experiment Video
Updated: Oct 23, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
SEC23A Inhibit Melanoma Metastatic through Secretory PF4 Cooperation with SPARC to Inhibit MAPK Signaling Pathway
Bin Zeng1, Zhiwei Sun1, Qiting Zhao1
1Institute of Life Sciences, Chongqing Medical University, Chongqing, China.
Abstract:
Metastasis of melanoma to the distant organs is a multistep process in which the tumor microenvironment (TME) may play an important role. However, the relationship between metastatic progression and TME is intricate. In the present study, using melanoma derivative cell lines OL (oligometastatic) and POL (polymetastatic) that differ in their metastatic colonization capability, we have elucidated a new mechanism involving "SEC23A-PF4-MAPK/ERK axis" in which PF4 transported by COPII hinders metastasis through inhibition of MAPK/ERK signaling pathway. Furthermore, SPARC can act cooperatively to enhance the inhibition of Pf4 on ERK phosphorylation and melanoma cell metastasis. Our findings show the possibility of targeting cancer cell secretome for therapeutic development.
Insights
Researchers discovered a new mechanism where Platelet Factor 4 (PF4) inhibits melanoma metastasis by blocking the MAPK/ERK pathway. SPARC enhances this effect, suggesting targeting the cancer cell secretome for new therapies.
Area of Science:
- Oncology
- Cancer Biology
- Molecular Mechanisms of Cancer
Background:
- Melanoma metastasis is a complex, multistep process.
- The tumor microenvironment (TME) significantly influences metastatic progression.
- Understanding the intricate relationship between TME and metastasis is crucial for developing effective treatments.
Purpose of the Study:
- To elucidate a novel mechanism regulating melanoma metastasis.
- To investigate the role of the SEC23A-PF4-MAPK/ERK axis in metastatic colonization.
- To explore the potential of targeting the cancer cell secretome for therapeutic strategies.
Main Methods:
- Utilized OL (oligometastatic) and POL (polymetastatic) melanoma cell lines with distinct metastatic capabilities.
- Investigated the function of Platelet Factor 4 (PF4) in metastasis.
- Examined the involvement of the MAPK/ERK signaling pathway and the protein SPARC.
Main Results:
- Identified a new mechanism where PF4, transported by COPII, inhibits melanoma metastasis.
- PF4 hinders metastasis by suppressing the MAPK/ERK signaling pathway.
- SPARC cooperates with PF4 to enhance the inhibition of ERK phosphorylation and melanoma cell metastasis.
Conclusions:
- The SEC23A-PF4-MAPK/ERK axis represents a key regulator of melanoma metastasis.
- SPARC enhances the anti-metastatic effects of PF4.
- Targeting the cancer cell secretome, specifically PF4 and SPARC interactions, offers a promising therapeutic avenue for melanoma treatment.
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Abnormal Proliferation

